Tyson Williams, DPM
Podiatrist · Minot, NDNPI 1679648745
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (48.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Arthrex at 54.1% of the total. Reporting peaked in 2022 at $3,580 and has fallen 94.6% since, to $194 in 2025.
Across 75 payments — averaging $133.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$5K
- Stryker$3K
- Sioux Surgical Inc$713
- Smith+Nephew$68
- Kerecis Limited$53
- Merck$48
- plus $213 from 9 others
What the payments were for
- Travel & lodging$3,76838%
- Food & beverage$1,35914%
- Education$4,86549%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 32 | $5,410 |
| Stryker | 22 | $3,487 |
| Sioux Surgical Inc | 1 | $713 |
| Smith+Nephew | 3 | $68 |
| Kerecis Limited | 3 | $53 |
| Merck | 3 | $48 |
| Johnson & Johnson | 1 | $40 |
| Integra Lifesciences Corporation | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 2 | $31 |
| Vertex | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $14 |
| Organogenesis Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few podiatrist providers in North Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 12 | $1,624 |
| Terbinafine Hcl | 61 | $1,203 |
| Pregabalin | 75 | $1,033 |
| Lidocaine | 12 | $641 |
| Meloxicam | 80 | $571 |
| Gabapentin | 47 | $546 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 58 | $372 |
| Cephalexin | 35 | $352 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 43 | $221 |
| Doxycycline Monohydrate | 11 | $186 |
| Hydromorphone Hcl | 18 | $129 |
| Tramadol Hcl | 22 | $96 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Minot
- Ashley EvanoffMinot$163
- Derek McListerFargo$46K
- Kayla EmterBismarck$9K
- Travis FitzkeFargo$9K
- Qianlin LiGrand Forks$8K
- Ryan JamesonFargo$7K
- Mark DomaasFargo$4K
- Lee HofsommerFargo$843
- Matthew KammererWahpeton$485
- Alisha JohnstonDevils Lake$338
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.